Lacosamide - UCB

Drug Profile

Lacosamide - UCB

Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒ

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Houston
  • Developer Daiichi Sankyo Company; UCB
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Generalised seizures; Tonic-clonic epilepsy
  • Phase II/III Epilepsy
  • No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 21 Nov 2017 UCB completes a phase III trial for Partial epilepsies (Monotherapy, In adolescents, In adults, In the elderly) in Japan (PO) (NCT02124564)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Germany (PO)
  • 03 Nov 2017 Registered for Partial epilepsies (Monotherapy, Adjunctive therapy, In adolescents, In children) in USA (PO, Liquid and PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top